hVIVO plc Exercise of Share Options (6197K)
23 September 2016 - 4:00PM
UK Regulatory
TIDMHVO
RNS Number : 6197K
hVIVO plc
23 September 2016
For immediate release 7.00am: 23 September 2016
HVIVO PLC
("hVIVO" or the "Company")
Exercise of Share Options
hVIVO plc (AIM: HVO), a specialty biopharma company with
clinical testing capabilities, announces that, following the
exercise of employee share options, application has been made to
AIM for the admission of 10,125 new ordinary shares of 5.0p each
(the "New Ordinary Shares").
Following admission of the New Ordinary Shares to trading on
AIM, the total number of ordinary shares with voting rights in
issue will be 78,090,310 and this figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
Admission of the New Ordinary Shares ("Admission"), which will
rank pari passu in all respects with the Company's existing shares
in issue, is expected to occur on 28 September 2016.
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries +44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and Public
Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with clinical
testing capabilities, is pioneering a human-based analytical
platform to accelerate drug discovery and development in
respiratory and infectious diseases. Leveraging human disease
models in flu, RSV, and asthma exacerbation, the hVIVO platform
captures disease in motion, illuminating the entire disease life
cycle from healthy to sick and back to health. Based in the UK,
market leader hVIVO has conducted more than 45 clinical studies,
inoculated over 2000 volunteers and has three First-In-Class
therapies currently in development with a growing pre-clinical
pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOELFFVLAFIFFIR
(END) Dow Jones Newswires
September 23, 2016 02:00 ET (06:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Mar 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024